Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science

Awarded

FDABAA-26-00123_AwardFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science, solicitation number FDABAA-26-00123_Award, was issued by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services. This award notice, posted on October 8, 2026, encompasses a total of 53 awards distributed among various universities and private firms. The projects are primarily focused on the advancement of regulatory science, specifically targeting FDA-regulated product development, the implementation of digital twins, and innovations in pharmaceutical manufacturing. Managed by primary point of contact Ian Weiss, the contracts are categorized under NAICS code 541714 and involve performance locations in Silver Spring, Maryland. The associated documentation provides a detailed breakdown of the final awards for Fiscal Year 2026, including specific contract numbers, obligated amounts, and total estimated values for each recipient. No set-aside was used for these awards, reflecting a broad competitive solicitation process to enhance the technical capabilities of regulatory oversight.

General Info

FDA FY26 awards for 53 entities advancing regulatory science and pharmaceutical manufacturing innovations.

Agency

Department Of Health And Human Services → FDA Office Of Acquisitions And Grants Services

Contract Value

$120,774,129

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Silver Spring, MD, 20993, USA

Set-Aside

NONE

Awardee

Please_See_Spreadsheet

Award Issued Date

09/30/2026, 12:00:00 AM UTC

Documents

1

Final FY26 Awards List

award

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseAwarded

PostedOct 8

Award Notice

AwardedSep 30

Contract was awarded

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → FDA Office Of Acquisitions And Grants Services

Contacts1 person available

OfficeRockville, MD, 20857, USA

Organization / AgencyDepartment Of Health And Human Services → FDA Office Of Acquisitions And Grants Services

Office AddressRockville, MD, 20857, USA

Contacts

Ian Weiss

contact@example.gov

+1 (555) 000-0000

Full Description

Show more

Please see attachment. 53 total awards from the subject announcment.

Similar Contracts

Same NAICS industry code

Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.

Defense Health Agency

POSTED

about 23 hours ago

DEADLINE

in about 1 month

Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.

Defense Health Agency

POSTED

about 23 hours ago

DEADLINE

in about 1 month

Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.

Defense Health Agency

POSTED

about 23 hours ago

DEADLINE

in about 1 month

Lupus Genetic & Biological Subset ResearchThe Lupus Genetic and Biological Subset Research subcontract involves providing specialized biological and genetic analysis to support prime contractors on Defense Health Agency research projects. The scope of work focuses on identifying and categorizing lupus patient subsets to enable targeted treatment through genomic sequencing, biomarker identification, biological assay development, and detailed patient cohort analysis. The primary deliverable for this effort is the provision of categorized biological and genetic data sets. This project is managed under the Department of Defense for the Defense Health Agency, with performance taking place in Frederick, Maryland. The opportunity was posted on October 14, 2026, with a response deadline of November 16, 2026. The work is classified under NAICS code 541714, reflecting its focus on research and development in the biotechnology field.

Defense Health Agency

POSTED

about 23 hours ago

DEADLINE

in about 1 month

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027LRP to gather feedback for the Lupus Research Program. This initiative aims to inform future focus areas and research funding opportunities for fiscal year 2027. The program is specifically seeking input from academia, industry, non-profit organizations, federal agencies, and the general public to identify critical gaps in the field and underfunded research areas. Strategic goals include improving the quality of life for patients, gaining insight into disease mechanisms and heterogeneity, and advancing the understanding of lupus patient subsets to optimize treatment. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. Consequently, no contract will be awarded based on this announcement, and there are no established deliverables or periods of performance. Interested parties are requested to provide their feedback via Survey Monkey by November 16, 2026, at 4:00 PM EST. While previous appropriations from fiscal years 2017 through 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated.

Defense Health Agency

POSTED

about 23 hours ago

DEADLINE

in about 1 month

DARPA Surgical Competition (DSC) Second Industry Day

Solicitation # DARPA-SN-27-02

Defense Advanced Research Projects Agcy

POSTED

about 23 hours ago

DEADLINE

NSF X-Labs Initiative - From Sequence to Function

Solicitation # NSF-Topic4-FY26-XLabsSequence-to-Function

Tip - Core Programs

POSTED

about 23 hours ago

DEADLINE

Preclinical In Vivo Efficacy TestingThis subcontract involves performing preclinical in vivo efficacy testing for vaccine candidates on behalf of prime contractors for NIH/NIAID malaria vaccine projects. The scope of work includes administering vaccines to vertebrate animal models, monitoring immune responses, and conducting tissue analysis and euthanasia. To qualify, the provider must maintain an AAALAC-accredited vivarium with specialized housing for malaria-susceptible species and strictly adhere to AVMA Guidelines for the Euthanasia of Animals. The primary deliverables for this engagement are comprehensive animal study reports and preclinical efficacy data. This opportunity is associated with NAICS code 541714 and is managed under the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is February 11, 2027.

National Institutes Of Health

POSTED

DEADLINE

Specialized Vaccine Formulation ServicesThis subcontract for Specialized Vaccine Formulation Services supports the National Institutes of Health and the Department of Health and Human Services in advancing preclinical malaria vaccine projects. The selected provider will develop and test improved formulations and combination vaccine strategies for prime contractors, utilizing laboratory-scale equipment, stability chambers, and analytical tools such as HPLC or Mass Spec. Key responsibilities include performing formulation screening, stability testing, and the creation of delivery systems while maintaining strict compliance with federal laboratory safety and biohazard regulations. The primary deliverables for this engagement are validated vaccine formulations and comprehensive stability reports. Interested parties should note that the response deadline is February 11, 2027, and the work falls under NAICS code 541714.

National Institutes Of Health

POSTED

DEADLINE

Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)The National Institutes of Health is seeking applicants to establish Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications. These centers will provide essential resources and testing services to the biomedical community to advance the development of genome editing technologies for treating human diseases. By collaborating with NIH-funded investigators, the centers will evaluate the efficacy and safety of delivery technologies, establish editing thresholds to minimize off-target effects, and determine feasibility within various model systems. The initiative emphasizes the creation of in vivo and in vitro research models, with a specific interest in new approach methodologies and human-biology-based models to complement traditional methods. Testing Centers are expected to develop standardized assays and operating procedures to ensure scientific rigor and reproducibility. While focusing on a limited number of initial projects, these centers will build adaptable core systems designed to support a wide range of diseases and offer fee-for-service resources on a local, regional, and national scale.

National Institutes Of Health

POSTED

DEADLINE

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-024

The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.

National Institutes Of Health

POSTED

DEADLINE

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-024

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking proposals under solicitation RFA-AI-28-024 to accelerate the research and preclinical development of next-generation malaria vaccines. This initiative focuses on utilizing structure-based immunogen design, advanced formulations, and combination vaccines to create long-lasting and highly effective protection. The ultimate objective is to enhance public health security in the United States and establish a developmental model that can be applied to other mosquito-borne diseases. This federal solicitation was posted on October 13, 2026, with a response deadline of February 12, 2027. The funding opportunity follows an R61/R33 structure and specifically notes that clinical trials are not allowed. Interested parties can find further details and submission guidelines through the official grants portal.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

More opportunities from Department Of Health And Human Services → FDA Office Of Acquisitions And Grants Services

Same awarding agency

Regulatory Decision Frameworks and Predictive ModelingThe contract involves the development of AI and machine learning-driven predictive models and decision support tools aimed at enhancing regulatory decision-making processes. Leveraging both high-quality scientific data and real-world data, the objective is to improve the accuracy and efficiency of regulatory evaluations. This initiative is critical for advancing the FDA's ability to assess and manage health-related risks more effectively. This subcontract falls under the NAICS code 541990 and is managed by the FDA Office of Acquisitions and Grants Services within the Department of Health and Human Services. The work will be performed in Silver Spring, Maryland, and focuses on creating frameworks that support regulatory decisions through sophisticated data analysis and predictive modeling techniques. The contract was posted in January 2026 and seeks specialized expertise to integrate innovative technologies into regulatory workflows.

All Other Professional, Scientific, and Technical Services

POSTED

DEADLINE

Clinical and Surrogate Endpoint Development for Regulatory ApprovalThis contract involves conducting research aimed at defining and validating clinical or surrogate endpoints to support regulatory submissions, with a particular focus on facilitating accelerated approval pathways. The work is designed to provide critical data that aids in meeting regulatory requirements, helping to streamline the approval process for new therapies or medical products. The subcontract, issued by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, falls under the NAICS code 541715, which typically includes research and development in the physical, engineering, and life sciences. The place of performance is located in Silver Spring, with the contract posted for potential subcontracting opportunities on January 13, 2026. The emphasis on endpoint development highlights the importance of scientific validation in advancing medical innovation through regulatory channels.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Patient Preference Information (PPI) Quantification StudiesThis contract involves designing and conducting studies to measure patient preferences in clinical decision-making, with a particular focus on rare diseases. The work will employ structured survey techniques alongside statistical methodologies to quantitatively assess how patients weigh different treatment options and outcomes, providing valuable insights to inform regulatory and healthcare decisions. The contract is a subcontract managed by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, with the place of performance in Silver Spring, Maryland. The effort falls under the NAICS code 541611, which pertains to administrative management and general management consulting services. The project aims to enhance understanding of patient perspectives to support more patient-centered healthcare and regulatory processes.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Digital Health Integration and Real-World Evidence (RWE) AnalyticsThe contract focuses on the development and validation of digital health tools along with the integration of real-world data into regulatory frameworks. This involves utilizing predictive modeling and data science techniques to enhance the analysis and application of real-world evidence in healthcare settings. The work aims to support regulatory decision-making by leveraging advanced analytics to better interpret and utilize data collected outside traditional clinical trials. Awarded by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, the subcontract is classified under the NAICS code 541715, which pertains to research and development in physical, engineering, and life sciences. The place of performance is located in Silver Spring, and the contract was posted in January 2026. This initiative underscores the agency’s commitment to harnessing innovative digital technologies and data-driven methodologies to improve public health outcomes through more effective regulatory science.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Botanical Drug Safety and Quality EvaluationThe contract involves conducting comprehensive analytical and preclinical studies to evaluate the safety, composition, and quality control of botanical drug products. This includes performing toxicology screenings and employing standardization methods to ensure the botanical drugs meet established safety and quality standards. The work is focused on supporting regulatory compliance and scientific validation of these products. Awarded by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, this subcontract falls under the NAICS code 541990, which pertains to specialized scientific services. The principal place of performance is located in Silver Spring, with the contract posted on January 13, 2026. The scope and nature of the contract emphasize the critical role of rigorous quality assessment for botanical drugs, contributing to public health protection and regulatory oversight.

All Other Professional, Scientific, and Technical Services

POSTED

DEADLINE

Regulatory Science Research in Tobacco Product AssessmentThe contract focuses on conducting comprehensive public health research related to tobacco product use, encompassing behavioral studies, clinical observations, and analysis of policy impacts. The research aims to generate evidence that will inform and support regulatory decisions made by the FDA, ensuring that the agency’s regulatory actions are grounded in robust scientific data. It addresses multiple facets of tobacco use and its implications, which is critical for evaluating products under FDA oversight. This subcontract, issued by the FDA Office of Acquisitions and Grants Services within the Department of Health and Human Services, is identified under NAICS code 541990 and will be performed in Silver Spring. The contract prioritizes research activities that contribute to tobacco product assessment through a regulatory science lens, facilitating the FDA’s mission to protect public health. The focus on evidence-driven analysis highlights the importance of integrating behavioral, clinical, and policy-related research elements to comprehensively understand tobacco product impacts.

All Other Professional, Scientific, and Technical Services

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS